Shaw AT, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 35, 2017 (suppl; abstr LBA9008).
Circulerend tumor-DNA toont maanden eerder dan scan of kankertherapie effectief is
nov 2023 | Dermato-oncologie, Uro-oncologie